Despite the usage of TRT approaches with radiolabeled antibodies (Bexxar and Zevalin) targeting CD20 receptors overexpressed in B-cell NHLs, similar strategies have not been successful for T-cell NHL mainly due to the lack of known tumor-specific markers and the inability to treat secondary T-cell aplasia resulting from targeting shared antigens with normal T-cells. This evidence concerns the gene MS4A1 and T-cell non-Hodgkin lymphoma.